Bayer (FRA:BAYN) has been assigned a €86.00 ($100.00) price target by analysts at Berenberg Bank in a report released on Tuesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. Berenberg Bank’s target price would indicate a potential upside of 14.82% from the company’s previous close.
A number of other equities research analysts also recently commented on BAYN. Goldman Sachs Group set a €77.00 ($89.53) target price on Bayer and gave the stock a “buy” rating in a research report on Monday, November 18th. UBS Group set a €110.00 ($127.91) target price on Bayer and gave the stock a “buy” rating in a research report on Tuesday, November 19th. DZ Bank reiterated a “neutral” rating on shares of Bayer in a research report on Thursday, October 31st. Barclays set a €85.00 ($98.84) target price on Bayer and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Nord/LB set a €64.00 ($74.42) target price on Bayer and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. Bayer currently has a consensus rating of “Hold” and a consensus price target of €79.94 ($92.95).
FRA:BAYN opened at €74.90 ($87.09) on Tuesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98). The business’s 50-day moving average is €71.61 and its 200 day moving average is €66.01.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: What are no-load funds?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.